Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.72 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.72 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.72 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.72 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.51 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 13/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | CCR2 | P41597 | 1/20 | 0.72 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898695 | 0.99 | CXCR4 (0.74) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL5962418 | 0.94 | CXCR4 (0.66) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL10006951 | 0.92 | CXCR4 (0.63) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL13995932 | 0.91 | SIGMAR1 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL10901935 | 0.91 | SIGMAR1 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL28273325 | 0.91 | SIGMAR1 (0.61) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL1160126 | 0.90 | SIGMAR1 (0.62) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Edetic Acid SCHEMBL2365124 | 0.88 | CXCR4 (0.59) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Plerixafor SCHEMBL414153 | 0.87 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Hydrochloric Acid SCHEMBL7612104 | 0.87 | CXCR4 (1.00) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919938-B2 | Modified cyclopentapeptides and uses thereof | Technische Universität München (DE) | 2021-02-16 | — | — | US | disclosed |
| US-20180037608-A1 | MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF | Technische Universität München (DE) | 2018-02-08 | — | — | US | disclosed |
| US-9266924-B2 | Cyclopentapeptide derivatives and uses thereof | Technische Universität München (DE) | 2016-02-23 | — | — | US | disclosed |
| US-20130129622-A1 | CYCLOPENTAPEPTIDE DERIVATIVES AND USES THEREOF | Technische Universität München (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2013344-B1 | ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE | BALTIC TECHNOLOGY DEV LTD (EE) | 2012-08-29 | — | — | EP | disclosed |
| US-20120171279-A1 | STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES | Baltic Technology Development Ltd. (EE) | 2012-07-05 | — | — | US | disclosed |
| EP-2380596-A1 | Cyclopentapeptide derivatives and uses thereof | Technische Universität München (DE) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380597-A1 | Cyclopeptide derivatives and uses thereof | Technische Universität München (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7786292-B2 | compounds having a chelating moiety and an oligonucleotide sequence which includes one or more modified nucleobases such as hydroxynucleobases; inhibiting translation of a nucleic acid in an organism | BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) | 2010-08-31 | — | — | US | disclosed |
| EP-2013344-A2 | ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE | Baltic Technology Development, Ltd. (EE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007125173-A2 | ANTISENSE AGENTS COMBINING STRONGLY BOUND BASE - MODIFIED OLIGONUCLEOTIDE AND ARTIFICIAL NUCLEASE | BALTIC TECHNOLOGY DEVELOPMENT, LTD. (EE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259830-A1 | Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease | BALTIC TECHNOLOGY DEVELOPMENT (EE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037608-A1 | MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF | ANXA4, CPA4, PTMS | CHRM2 2066/4885CHRM1 1524/4885ADRA2C 1299/4885 |
| US-20070259830-A1 | Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease | NCL, RNGTT, POLRMT | CHRM2 4847/4885CHRM1 4856/4885ADRA2C 4810/4885 |
| US-20130129622-A1 | CYCLOPENTAPEPTIDE DERIVATIVES AND USES THEREOF | ANXA4, XPNPEP1, ANXA1 | CHRM2 3421/4885CHRM1 1739/4885ADRA2C 2120/4885 |
| US-20120171279-A1 | STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES | POLRMT, RNGTT, NSUN2 | CHRM2 4850/4885CHRM1 4842/4885ADRA2C 4793/4885 |
| US-10919938-B2 | Modified cyclopentapeptides and uses thereof | ANXA4, CPA4, PTMS | CHRM2 2066/4885CHRM1 1524/4885ADRA2C 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.